U.S. Software Stock News

Enphase Energy stock is caught between mixed valuation signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a premium to today’s price while market based multiples screen as more supportive, all against a five year share price record that has been heavily negative. Over the last 5 years, Enphase Energy has delivered a share price decline of 77.0%, which sets a cautious backdrop for any valuation case today. On the upside, new products such as the IQ9N...

In the days leading up to its 22 July 2026 earnings release, GE Vernova drew attention as analysts pointed to strong anticipated second‑quarter results supported by AI data center–driven power demand and a growing backlog in its Power and Electrification segments, even as the Wind business continued to face project delays and supply‑chain issues. An interesting angle is GE Vernova’s decision to commit US$11 billion to capital expenditure and R&D through 2028 to capture AI‑related power and...

UnitedHealth Group (UNH) is back in focus after reporting second quarter results that beat expectations on revenue and adjusted earnings, lifting full year profit guidance and sending the stock sharply higher. See our latest analysis for UnitedHealth Group. The latest jump in UnitedHealth Group’s share price comes on top of a 30.42% 90 day share price return and a 50.91% total shareholder return over the past year. This suggests momentum has rebuilt after the 2025 setback, and the recent...

In July 2026, Arovella Therapeutics announced a collaboration under which Charles River Laboratories International will provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing to support ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. This partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...

Lenivia launch puts Zoetis stock back on investors’ radar Zoetis (ZTS) has just rolled out Lenivia, a long acting monoclonal antibody therapy for canine osteoarthritis pain, offering up to three months of relief from a single injection in Canada and the EU. See our latest analysis for Zoetis. Despite the Lenivia launch and recent vaccine approvals in Europe, Zoetis has been under pressure, with the share price at $76.91 and the year to date share price return down 38.9%, while the 1 year...

BigBear.ai recently expanded its generative AI platform for Department of War mission teams, adding new air-gapped hardware, flexible tenant setups, and both cloud-connected and fully local deployment options across classified environments. A key shift is the move from the Ask Sage brand to a refactored, model-agnostic BigBear.ai platform that lets agencies separate secure workspace licensing from their own “bring-your-own-model” procurement. Now we’ll examine how the new air-gapped,...

Lower fertilizer tariffs, potential trade policy shifts and closer regulatory attention on industry giants are reshaping the playing field for U.S. agricultural producers. For investors, that mix of lower input costs and fresh policy uncertainty can create both opportunity and risk across related stocks. This article focuses on three U.S. Agricultural Producers screener stocks that are directly exposed to the latest fertilizer and trade headlines, and explains how these developments might...

ASP Isotopes Inc. recently filed a shelf registration statement to issue up to US$106.08 million of common stock, covering 23,160,682 shares. This sizeable shelf registration gives the company flexibility to access equity capital quickly, which could shape how investors view its future financing plans. We will now examine how this sizeable shelf registration shapes ASP Isotopes' investment narrative and what it may imply for future capital needs. The future of work is here. Discover the 32...

Main Street Capital recently reported preliminary second-quarter 2026 results showing favorable distributable net investment income and its sixteenth consecutive quarterly increase in net asset value per share, driven primarily by fair value gains in its lower middle market and private loan portfolios. At the same time, analysts are increasingly cautious as income growth slows and management continues to raise regular and supplemental dividends, sharpening questions about the balance between...

Cybin, operating as Helus Pharma, has advanced its lead psychedelic candidate HLP003 into an ongoing Phase 3 trial for adjunctive treatment of major depressive disorder and recently raised about US$50,000,000 in an underwritten public offering to support its development programs. This combination of late-stage clinical progress and fresh funding highlights how Cybin is positioning HLP003 within the evolving landscape of interventional psychiatry for depression care. We’ll now explore how the...

Etsy stock has staged a sharp recovery in the last year, yet its longer term shareholders are still sitting on a steep decline, and the valuation checks are sending mixed messages as the Discounted Cash Flow (DCF) intrinsic value estimate points to a discount while earnings based multiples lean expensive. Over 5 years, Etsy shares have declined 58.6%, which frames the current price against a much weaker long term return profile for existing holders. The approved sale of Depop to eBay for...

Cintas (CTAS) has wrapped up FY 2026 with fourth quarter revenue of US$2.9 billion and basic EPS of US$1.28, supported by trailing 12 month revenue of US$11.3 billion and basic EPS of US$4.98 that reflects earnings growth of about 10.7% over the past year. Over recent periods, the company has seen quarterly revenue move from US$2.67 billion in Q4 FY 2025 to US$2.91 billion in Q4 FY 2026, while basic EPS rose from US$1.11 to US$1.28. Those top line and per share gains are backed by a modest...

With inflation signals mixed across regions, policy makers weighing their next moves and growth momentum differing sharply from one economy to another, many investors are looking for stocks that pair earnings growth potential with balance sheet strength. The Healthy high growth potential screener focuses on companies that analysts expect to grow earnings over the next 3 years while staying in acceptable financial shape, which can be appealing when bond yields, export demand and consumer...

PFAS Funding Support Puts Essential Utilities in Focus Aqua Pennsylvania, a subsidiary of Essential Utilities (WTRG), recently secured $74.3 million in principal forgiveness and low-interest loans from PENNVEST to fund PFAS treatment projects across its service territory. This funding backs a planned PFAS treatment system at the Neshaminy Water Treatment Plant, serving about 62,000 customers, and additional installations at community well sites in Chester and Luzerne Counties, bringing...

Alexandria Real Estate Equities (ARE) has moved to lock in a new source of liquidity with an escrow agreement covering signatures for a fourth amended and restated credit facility that could total up to US$6 billion. See our latest analysis for Alexandria Real Estate Equities. At a share price of US$50.14, Alexandria Real Estate Equities has seen a 2.96% 1 day share price return and a 3.36% 7 day share price return, while the 1 year total shareholder return is down 32.57%. This suggests...

Leadership and Product Shifts Put Klaviyo Stock in Focus Klaviyo (KVYO) is in focus after appointing Erica Smith as Chief Financial Officer and principal financial and accounting officer, alongside launching its Klaviyo Social Marketing product for CRM-linked social media campaigns. See our latest analysis for Klaviyo. The leadership changes and Klaviyo Social Marketing launch come after a mixed share price pattern, with a 30 day share price return of 28.76% contrasting with a year to date...

Agenus recently announced an oversubscribed private placement of up to US$340 million, including a US$85,000,000 Regulation D securities purchase agreement with institutional investors such as Commodore Capital, RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals, alongside board expansion to add two Commodore-designated directors. The financing follows three-year Phase 1b data showing durable BOT+BAL responses in heavily pretreated MSS metastatic colorectal cancer, reinforcing...

COMPASS Pathways (NasdaqGS:CMPS) is back in focus after reporting 26 week Phase 3 COMP006 data for its COMP360 psilocybin candidate in treatment resistant depression, alongside supportive regulatory progress and new PTSD analysis. See our latest analysis for COMPASS Pathways. Despite the latest positive trial readout, COMPASS Pathways' share price has been volatile, with a 1 day share price return that declined 6.61% and a 7 day share price return that declined 8.60%. However, the 90 day...

Netflix reported past second-quarter 2026 results with revenue of US$12.56 billion and net income of US$3.40 billion, alongside modest earnings-per-share growth versus a year earlier. The company paired these mixed results with softer third-quarter guidance and plans to reduce viewership disclosures, raising fresh questions about underlying engagement and growth drivers. We’ll now examine how softer third-quarter guidance and scaled-back viewership reporting reshape Netflix’s investment...

Why Albemarle Stock Is Back on Investors' Radar Upward revisions to earnings estimates and a recent upgrade to a buy rating have pushed Albemarle (ALB) into the spotlight, drawing more investor attention as expectations for this quarter's results gain traction. See our latest analysis for Albemarle. Despite the more positive earnings outlook, Albemarle's recent share price performance has been weak. The stock closed at US$119.46 and recorded a 30 day share price return that is down 28.08%...

Caris Life Sciences has had a difficult year for shareholders, with the stock down 47.3% over the past 12 months, yet its valuation checks still lean toward the shares looking cheap rather than expensive. With fresh product news in precision oncology and multi cancer screening, the question is whether the market is being too cautious or the valuation score is missing important risks. Over the last year, Caris Life Sciences has declined 47.3%, which suggests sentiment around the stock has...

Cloudera and VAST Data have announced a strategic partnership to enhance the accessibility and efficiency of AI data platforms across enterprises. By integrating Cloudera’s lakehouse data services with VAST’s AI Operating System and leveraging NVIDIA’s AI Data Platform reference design, the collaboration aims to resolve common challenges like GPU starvation. This integrated solution, designed for enterprises operating in both on-premises environments and public clouds, promises to streamline...

With annual inflation in New Zealand expected around 4% to 4.2% and fuel costs surging, the gap between rising living costs and the returns on cash is back in focus for income investors. Higher inflation and the prospect of further Reserve Bank of New Zealand rate hikes can pressure equity valuations, but they also sharpen interest in stocks that already offer strong dividend metrics and robust balance sheets. This article looks at how that backdrop connects to our High Dividend Yield Stocks...

United Parcel Service (UPS) is back in focus as investors weigh perceived undervaluation, ongoing concerns about its large U.S. Postal Service contract, a recent legal settlement, and fresh spending on AI driven logistics improvements. See our latest analysis for United Parcel Service. At a share price of $117.18, UPS has logged a 16.0% year to date share price return and a 25.87% total shareholder return over one year. The 3 year and 5 year total shareholder returns remain in decline, which...